Roche pushes ahead with late-comer strategy in obesity

The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.

By Amy Baxter • July 30, 2025

Dr. Vinay Prasad, controversial FDA official, abruptly departs agency

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.

By Ben Fidler • July 30, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Could bispecifics unseat Keytruda from its oncology throne?

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

By Kelly Bilodeau • July 28, 2025

From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity

The studies are contributing preclinical advances for some of the world’s biggest blockbusters.

By Michael Gibney • July 25, 2025

Pharma’s turbo spending spree on US manufacturing

The industry’s push to expand American drug production isn’t abating as threats of tariffs loom.

By Meagan Parrish • July 24, 2025

How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

By Alexandra Pecci • July 24, 2025

Who is Dr. George Tidmarsh, the new director of CDER?

Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.

By Meagan Parrish and Michael Gibney • July 23, 2025

Novartis’ Zolgensma sales fall again as gene therapy market woes persist

Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?

By Michael Gibney • July 22, 2025

3 major patent losses this year — and a key strategy to fill the gaps

Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.

By Kelly Bilodeau • July 21, 2025

Why FDA’s CRL release could open the door to lawsuits against pharma

In a push for “radical transparency” the FDA released 200 CRLs for drugs that were later approved — some of which are now public for the first time.

By Meagan Parrish • July 18, 2025

J&J accelerates past Stelara’s fall with better-than-expected portfolio growth

Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.

By Michael Gibney • July 17, 2025

FDA invites more data from abroad — with a wary eye on China

The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.

By Amy Baxter • July 16, 2025

Need a DTC platform? Here’s how one company built its own.

Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med. 

By Amy Baxter • July 14, 2025

With Verona deal, Merck wagers on strength of lung drug’s patents

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.

By Jonathan Gardner • July 11, 2025

Pricing watchdog will take on the rising cost of drugs at launch

ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from a patient perspective.

By Michael Gibney • July 10, 2025

Trump says ‘very high’ pharmaceutical tariffs coming soon

While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.

By Phil Neuffer • July 9, 2025

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

Simone Steiner recently joined the French company to set the stage for launch.  

By Amy Baxter • July 9, 2025

The MEK effect on cancer — a slow and steady approach to drug resistance

Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

By Kelly Bilodeau • July 8, 2025

Is biopharma dealmaking getting hot again?

With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.

By Michael Gibney • July 8, 2025

GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down

As more drugmakers aim for the lucrative weight loss market, patient challenges linger.

By Amy Baxter • July 7, 2025

Can China sustain a surge in oncology drug innovation?

The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.

By Kelly Bilodeau • July 2, 2025

A biopharma bolsters patient centricity and trial diversity goals through newly created role

Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.

By Alexandra Pecci • July 1, 2025

AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

By Michael Gibney • July 1, 2025

FDA’s new mission to speed drug reviews

FDA Commissioner Dr. Marty Makary is leading a handful of controversial new initiatives to make the drug review process more streamlined.

By Amy Baxter • June 30, 2025

3 of the year’s most notable FDA nods

The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.

By Meagan Parrish • June 27, 2025